Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

#2109

Introduction: High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin +etoposide) is considered standard first-line palliative treatment. Etoposide is frequently administered intravenously, however oral etoposide is often used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- & intrapatient variability and patient compliance.

Aim(s): We aimed to compare differences in progression free survival (PFS) and overall survival (OS) in patients treated with oral etoposide, short infusion and long infusion.

Materials and methods: Patients (n=236) from the Nordic NEC study were divided into three groups receiving etoposide as along infusion (24h, n=170), short infusion (<5h, n=33), or oral etoposide (n=33). PFS and OS were analyzed with Kaplan-Meier (estimated with log-rank statistics), cox proportional hazard ratios (HRs) and confidence intervals (CIs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ali A

Authors: Ali A, Grönberg M, Hjortland G, Grønbæk H, Ladekarl M,

Keywords: chemotherapy, Neuroendocrine Neoplasms, Intravenous, Oral, survival,